Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, reported financial results for the second quarter ended June 30, 2021 and provided a business update.
August 6, 2021
· 12 min read